John Libbey Eurotext

Epileptic Disorders

The Educational Journal of the

Association between ABCB1 polymorphism and response to sodium valproate treatment in Malaysian epilepsy patients Volume 13, issue 1, Mars 2011

Authors
Pharmacogenomics Laboratory, Department of Pharmacology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Division of Neurology, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Division of Neurology, Department of Medicine, Faculty of Medicine, National University of Malaysia, Kuala Lumpur, Department of Pediatrics, Faculty of Medicine, University of Monash, Kuala Lumpur, Department of Pediatrics, Faculty of Medicine, National University of Malaysia, Kuala Lumpur, Medical Molecular Biology Institute, National University of Malaysia, Kuala Lumpur, Malaysia
  • Key words: epilepsy, ABCB1, polymorphism, P-glycoprotein, antiepileptic drug, sodium valproate
  • DOI : 10.1684/epd.2011.0419
  • Page(s) : 65-75
  • Published in: 2011

Over-expression of P-glycoprotein, encoded by the ABCB1 gene, is proposed to be involved in resistance to antiepileptic drugs in about 30% of patients with epilepsy. Here, we investigated the possible association between ABCB1 polymorphisms and sodium valproate (VPA) treatment in Malaysian epilepsy patients. Genotypes were assessed in 249 drug-resistant and 256 drug-responsive Malaysian patients for C1236T, G2677T/A, and C 5T polymorphisms in the ABCB1 gene. No genotypes, alleles, or haplotypes were associated with the response to VPA in either the overall group or Chinese, Indian, and Malay subgroups. Our data suggest that C1236T, G2677T/A, and C3435T polymorphisms in the ABCB1 gene do not contribute to the response to VPA in patients with epilepsy.